BioLineRX
BLRX
13 hedge funds and large institutions have $3.69M invested in BioLineRX in 2020 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
8% more funds holding
Funds holding: 12 → 13 (+1)
0% less ownership
Funds ownership: 0.04% → 0.04% (-0%)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
40% less capital invested
Capital invested by funds: $6.14M → $3.69M (-$2.46M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$174K |
| 2 |
Jane Street
New York
|
+$103K |
| 3 |
LPL Financial
San Diego,
California
|
+$21.6K |
| 4 |
CCB
Cutter & Co Brokerage
Ballwin,
Missouri
|
+$3.96K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Senvest Management
New York
|
-$208K |
| 2 |
CAN
Cetera Advisor Networks
El Segundo,
California
|
-$23K |
| 3 |
NFG
Next Financial Group
Houston,
Texas
|
-$1.58K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BI
1
BVF Inc
San Francisco,
California
| $2.31M | – | – | – |
|
|
SM
2
Senvest Management
New York
| $697K | -$208K | -2,619 | -17% |
|
|
3
Morgan Stanley
New York
| $457K | +$174K | +2,198 | +34% |
|
|
O
4
OrbiMed
New York
| $92K | – | – | – |
|
|
5
Jane Street
New York
| $77K | +$103K | +1,301 | New |
|
|
OM
6
Opaleye Management
Boston,
Massachusetts
| $22K | – | – | – |
|
|
CCB
7
Cutter & Co Brokerage
Ballwin,
Missouri
| $18K | +$3.96K | +50 | +17% |
|
|
8
LPL Financial
San Diego,
California
| $14K | +$21.6K | +272 | New |
|
|
NFG
9
Next Financial Group
Houston,
Texas
| $5K | -$1.58K | -20 | -18% |
|
|
RE
10
RBC Europe
London,
United Kingdom
| $17 | – | – | – |
|
|
CAN
11
Cetera Advisor Networks
El Segundo,
California
| – | -$23K | -250 | Closed |
|
12
Osaic Holdings
Scottsdale,
Arizona
| – | +$238 | +3 | New |
|
BLRX Hedge Fund Activity: Q1 2020 in Review
13 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in BioLineRX (BLRX) for Q1 2020, worth a combined $3.69M — down 40% from $6.14M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new BLRX positions and 1 closed out — a net gain of 2 holders — while 2 added to existing stakes and 2 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $174K. The largest seller was Senvest Management, cutting an estimated $208K.
- 13 institutional investors held BioLineRX (BLRX) as of Q1 2020, up from 12 in Q4 2019.
- Funds reported $3.69M of BioLineRX stock for Q1 2020, down 40% quarter-over-quarter.
- 3 funds opened new BioLineRX positions in Q1 2020 and 1 closed out, a net change of +2 holders.
- The largest BioLineRX buyer in Q1 2020 was Morgan Stanley, an estimated $174K added.
- The largest BioLineRX seller in Q1 2020 was Senvest Management, an estimated $208K sold.
Based on aggregated 13F filings for Q1 2020.